Jade Biosciences, Inc.
JBIO evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $1.22B
- Lead Asset:
- av-101 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for JBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JBIO
Jade Biosciences, Inc. (JBIO) is a clinical-stage biotechnology company developing best-in-class therapies for autoimmune diseases, with lead programs targeting IgA nephropathy and rheumatoid arthritis.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 4 clinical trials for Jade Biosciences, Inc..
Jade Biosciences, Inc. (JBIO) is a clinical-stage biotechnology company developing best-in-class therapies for autoimmune diseases, with lead programs targeting IgA nephropathy and rheumatoid arthritis.
- Cash & equivalents of $107.2M as of 2026-06-30 [sec].
- Lead candidate JADE101 (anti-APRIL mAb) is in Phase 2 for IgA nephropathy; interim Phase 1 results were shared in June 2026 [news · published 2026-06-01].
- JADE201 (afucosylated mAb targeting BAFF-R) entered Phase 1 in May 2026 for rheumatoid arthritis [news · published 2026-05-26].
- Preclinical candidate AV-101 (imatinib dry powder inhaled) is in development for pulmonary arterial hypertension [pipeline].
- The company completed a reverse merger and commenced trading on Nasdaq as JBIO in 2025, raising ~$300M in financing [news · published 2025-05-15].
What works
- Strong cash position of $107.2M as of 2026-06-30 provides runway through at least 2027 [sec][news · published 2025-05-15].
- JADE101 targets a validated pathway (APRIL) in IgAN with a quarterly dosing strategy that could improve adherence [news · published 2026-08-19].
- Multiple pipeline candidates (JADE101, JADE201, AV-101) address large autoimmune and pulmonary indications [pipeline].
What to weigh
- Net loss of -$55.8M as of 2026-06-30 reflects ongoing R&D spending without approved products [sec].
- JADE101 faces stiff competition from several late-stage IgAN candidates (e.g., sibeprenlimab, zigakibart, atacicept) [pipeline].
- JADE201 is only in Phase 1, with interim data not expected until 2027, leaving a long development timeline [news · published 2026-05-26].
From the filings
Quoted directly from source documents.
JADE101 Phase 1 interim results shared in June 2026
“On June 1, 2026, Jade Biosciences, Inc. ("Jade" or the "Company") will host a conference call and webcast to share interim results from its Phase 1 healthy volunteer trial evaluating JADE101”
News · June 1, 2026
Reverse merger and $300M financing
“Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027”
News · May 15, 2025
Catalyst timeline
- 2025-08-17 · Phase 1 start for JADE101 (healthy volunteers) — First Phase 1 study of JADE101 initiated in healthy volunteers.
- 2026-05-01 · Phase 1 start for JADE101 (Japanese/Chinese participants) — Additional Phase 1 study of JADE101 in Japanese and Chinese healthy volunteers.
- 2026-05-19 · Phase 1 start for JADE201 — First Phase 1 study of JADE201 initiated in participants.
Risks & what to watch (3)›
Key risks
- No approved products — All candidates are preclinical or early-stage; no revenue from product sales [pipeline].
- Competitive IgAN landscape — JADE101 competes with multiple Phase 2/3 IgAN candidates from Otsuka, Novartis, Vera, RemeGen, Vertex [pipeline].
- Long timeline for JADE201 — JADE201 Phase 1 interim data not expected until 2027; development risk remains [news · published 2026-05-26].
What to watch
- JADE101 Phase 2 data in IgAN (no specific date announced) [pipeline].
- JADE201 Phase 1 interim results expected in 2027 [news · published 2026-05-26].
- AV-101 preclinical advancement into Phase 1 for pulmonary arterial hypertension [pipeline].
- Cash runway updates as net losses continue [sec].
Sources: Catalysts · News · Pipeline · Generated October 2, 2026 · How we verify sources →
Run Jade Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Jade Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.07 · 0% dilution
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
120
Total value held
$735.7M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 7,085,423 | $99.6M |
| fairmount funds management llc | 4,553,494 | $64.0M |
| avidity partners management lp | 2,801,416 | $53.9M |
| ra capital management, l.p. | 3,671,083 | $51.6M |
| bellevue group ag | 3,501,502 | $49.2M |
| venrock adviser, llc | 3,220,364 | $45.2M |
| janus henderson group plc | 3,105,669 | $43.6M |
| blackrock, inc. | 2,313,949 | $32.5M |
| vanguard capital management llc | 1,796,652 | $25.2M |
| baker bros. advisors lp | 1,641,137 | $23.1M |
Showing top 10 of 120 institutional holders of Jade Biosciences, Inc.. Open the full 13F history after sign-in.
Governance
Frequently asked questions
What is the AI investment thesis for Jade Biosciences, Inc.?
Jade Biosciences, Inc. (JBIO) is a clinical-stage biotechnology company developing best-in-class therapies for autoimmune diseases, with lead programs targeting IgA nephropathy and rheumatoid arthritis.
What is Jade Biosciences, Inc.'s lead drug candidate?
Jade Biosciences, Inc.'s most advanced tracked candidate is av-101 (Preclinical) for pulmonary arterial hypertension.
Who is the CEO of Jade Biosciences, Inc.?
Mr. Tom Frohlich is the chief executive officer of Jade Biosciences, Inc. (JBIO).
Where is Jade Biosciences, Inc. headquartered?
Jade Biosciences, Inc. (JBIO) is headquartered in Waltham, MA, United States.
What therapeutic areas does Jade Biosciences, Inc. focus on?
Jade Biosciences, Inc. develops therapies across Immunology, Cardiovascular, Respiratory, Dermatology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.